Clinical Trial Update: Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC [Phase 3]

View source ↗

Summary

Phase III study evaluating toripalimab plus chemotherapy versus placebo plus chemotherapy in resectable stage II-III non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Toripalimab (Toripalimab)

Snippet

Sponsor: Shanghai Junshi Bioscience Co., Ltd. | Conditions: Stage II-III Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED